Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus (Q39451977)

12 September 2017

title

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus (English)

1 reference

12 September 2017

0 references

1 reference

W B White

1

1 reference

12 September 2017

R Pratley

2

1 reference

12 September 2017

P Fleck

3

1 reference

12 September 2017

M Munsaka

4

1 reference

12 September 2017

M Hisada

5

1 reference

12 September 2017

C Wilson

6

1 reference

12 September 2017

V Menon

7

1 reference

12 September 2017

publication date

4 April 2013

1 reference

Diabetes, Obesity and Metabolism

12 September 2017

published in

1 reference

12 September 2017

volume

15

1 reference

12 September 2017

issue

7

1 reference

12 September 2017

page(s)

668-673

1 reference

Epidemiology of cardiovascular complications in type 2 diabetes mellitus

12 September 2017

cites work

1 reference

Diabetes mellitus, fasting glucose, and risk of cause-specific death

21 January 2018

1 reference

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes

21 January 2018

1 reference

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

Alogliptin: a Novel Molecule for Improving Glycemic Control in Type II Diabetes Mellitus

21 January 2018

1 reference

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

Cardiovascular Effects of Glucagonlike peptide–1 Agonists

21 January 2018

1 reference

Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis

21 January 2018

1 reference

Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies

21 January 2018

1 reference

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study

21 January 2018

1 reference

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

21 January 2018

1 reference

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study

21 January 2018

1 reference

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12093

1 reference

12 September 2017

1 reference